1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Targeted Therapies in Asthma: KOL Insight [2018]

Targeted Therapies in Asthma: KOL Insight [2018]

  • February 2018
  • ID: 5355981
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

Can new biologics breathe fresh competition into the targeted asthma treatment landscape?
The severe asthma treatment landscape is evolving. Near-term debates will focus on how best to use currently approved treatments, including Xolair, Nucala and Cinqair/Cinqaero, and which treatments offer the best for patients. Visible on the horizon is another anti-IL-5 mAb, AstraZeneca’s Fasenra (benralizumab), and by all accounts KOLs believe it could take the market by storm. Longer-term, Xolair biosimilars are looking large in the minds of KOLs, as are next-generation biologics such as AstraZeneca/Amgen’s tezepelumab, and an anti-TSLP mAb currently in mid-stage testing but already generating highly compelling data.

Learn how the world’s leading asthma KOLs see the market evolving, how current products can protect market share, and how developers can differentiate their pipeline therapies in KOL Insight: Targeted Therapies in Asthma. Ten North American and European KOLs provide their insight on 3 marketed products and 10 pipeline programmes.

Take a tour of the report now
• The table of contents >
• The key business questions answered >
• The key KOL quotes >
• See the therapies covered >
• Find out who the 6 EU & 4 US KOLs are >
• Review an extract from the report - 1 drug profile >

Top takeaways
• Will Xolair (omalizumab) remain the treatment of choice for allergic asthma patients? Xolair may remain first-line-therapy for allergic asthma patients with elevated serum IgE levels, but for some patients other treatment options might be a better strategy. Moreover, omalizumab biosimilars are on the horizon. Find out what KOLs think about biosimilars, and how Xolair’s position in the treatment paradigm could change.
• What have been the key changes to the anti-IL-5 mAb landscape, and how do KOLs see this class evolving? Nucala (mepolizumab) was the first mAb to receive approval for severe asthma in over a decade, but other anti-IL5 mAbs are gaining traction. Of these, KOLs are most excited about AstraZeneca’s Fasenra (benralizumab). Find out what’s exciting KOLs, and what companies behind currently marketed anti-IL-5s can do to protect market share.
• What pipeline programmes are KOLs particularly excited about? Regeneron/Sanofi’s anti-IL-4/IL-13 mAb, dupilumab, is emerging as a potentially new treatment option for severe asthma, but its another pipeline programme that KOLs are raving about. Is it AstraZeneca/Amgen’s tezepelumab? Novartis’ fevipiprant? Or something else? Read the report to find out more.
• What’s the future of biomarkers in identifying responsive patients? With precision medicine becoming a critical enabler of product use in a number of disease areas, find out what KOLs think about the use of biomarkers in defining eligible patient populations in the severe asthma market and how this could help eliminate “trial and error” approaches to treatment decisions.
• With increasing number of biological therapies coming to market in the medium term, what will it take to succeed in the targeted asthma market? Competition for a limited pool of patients could eventually make the targeted asthma treatment landscape a less commercially attractive option for manufacturers developing new therapies in this field. What commercial strategies are KOLs advocating? As simple as strategic pricing, or are other strategies needed?

Quotes

“It’s got some advantages because it’s got this unique mechanism of action, it’s different. So there’s a story you can build on.” European Key Opinion Leader
“The thing about the anti-TSLP is that it’s further up the food chain in the inflammatory cascade and it may, potentially, make the other compounds redundant. So I think it’s very promising.” US Key Opinion Leader

Sample of therapies covered

Marketed/Registered Therapies
• Xolair (omalizumab; Roche/Novartis)
• Nucala (mepolizumab; GSK)
• Cinqair/Cinqaero (reslizumab, Teva)

Pipeline/Pre-Registered Therapies
• Benralizumab (anti-IL-5; AstraZeneca)
• Fevipiprant (anti-CRTh2; Novartis)
• Tralokinumab (anti-IL13; AstraZeneca)
• Dupilumab (anti-IL-4/IL-13; Sanofi/Regeneron)
• Risankizumab (anti-IL-23; Boehringer Ingelheim/AbbVie)
• Tezepelumab (anti-TSLP; AstraZeneca/Amgen)
• Xmab 7195 (anti-IgE/CD32b; Xencor)
• Bertilimumab (anti-CCL11 chemokine; Immune Pharmaceuticals)
• REGN 3500 (anti-IL-33; Sanofi/Regeneron)
• FB 825 (Anti-C'mX; Fountain Biopharma)

KOLs interviewed

KOLs from North America
• Dr Leonard B. Bacharier MD, Professor of Pediatrics and Clinical Director, Division of Allergy, Immunology and Pulmonary Medicine at Washington University School of Medicine in St. Louis, USA
• Dr Mark J. Fitzgerald MD, Director at the Centre for Heart and Lung Health at Vancouver Coastal Health Research Institute, Vancouver, Canada
• Dr Mike E. Wechsler MD, MMSc, Associate Physician, Brigham and Women’s Hospital, Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA
• Dr Mitchell Grayson MD, Nationwide Children Hospital’s Chief of the Division of Allergy and Immunology for The Ohio State University Department of Pediatrics, Columbus, Ohio, USA

KOLs from Europe
• Professor Arnaud Bourdin, MD, Head of General Pneumology, CHU de Montpellier, Montpellier, France
• Professor Andy Wardlaw, MD, Head of Department and Professor of Respiratory Medicine, Glenfield Hospital, Leicester, UK
• Professor Kian Fan Chung, MD, Professor of Respiratory Medicine, Royal Brompton Hospital, London, UK
• Professor Peter J Barnes, MD, Professor of Thoracic Medicine and Head of Respiratory Medicine at the National Heart and Lung Institute and Honorary Consultant Physician at Royal Brompton Hospital, London, UK
• Anonymous German KOL, Professor at a leading university in Germany specialising in asthma and respiratory medicine
• Anonymous German KOL, Professor at a leading university in Germany specialising in asthma, pulmonary medicine and critical care

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2019: Deal trends, players and financials

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2019: Deal trends, players and financials

  • $ 2995
  • November 2019

The Global Cancer Monoclonal Antibody Partnering 2014-2019: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals ...

Monoclonal Antibody Markets in China

Monoclonal Antibody Markets in China

  • $ 4000
  • October 2019

China’s demand for Monoclonal Antibody has grown at a fast pace in the past decade.In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth ...

Global Antibody Partnering Terms and Agreements 2014-2019: Deal trends, players and financials

Global Antibody Partnering Terms and Agreements 2014-2019: Deal trends, players and financials

  • $ 2995
  • November 2019

The Global Antibody Partnering Terms and Agreements 2014 to 2019 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the ...


ref:plp2018

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on